RCMW Group Inc Ordinary Shares Stock (OTC: RCMW)

Latest news for RCMW Group Inc Ordinary Shares (OTC:RCMW) Stock

RCMW Group Inc Ordinary Shares

DA Davidson analyst Peter Heckmann maintains SS&amp;C Techs Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSNC#NASDAQ">SSNC</a>) with a Buy and raises the price target from $88 to $92.

News

Price Target

Analyst Ratings

SSNC

DA Davidson Maintains Buy on SS&C Techs Hldgs, Raises Price Target to $92

Cantor Fitzgerald analyst Sarah James reiterates Health Catalyst (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAT#NASDAQ">HCAT</a>) with a Overweight and maintains $16 price target.

Reiteration

HCAT

Cantor Fitzgerald Reiterates Overweight on Health Catalyst, Maintains $16 Price Target

Wells Fargo analyst Andrew Bauch maintains Shift4 Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) with a Overweight and raises the price target from $75 to $95.

FOUR

Wells Fargo Maintains Overweight on Shift4 Payments, Raises Price Target to $95

Cantor Fitzgerald analyst Sarah James reiterates Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) with a Overweight and maintains $600 price target.

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Cantor Fitzgerald Reiterates Overweight on Elevance Health, Maintains $600 Price Target

Wells Fargo analyst Colin Langan maintains TE Connectivity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEL#NYSE">TEL</a>) with a Equal-Weight and lowers the price target from $155 to $153.

Wells Fargo Maintains Equal-Weight on TE Connectivity, Lowers Price Target to $153

Cantor Fitzgerald analyst Sarah James reiterates DocGo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCGO#NASDAQ">DCGO</a>) with a Overweight and maintains $5 price target.

DCGO

Cantor Fitzgerald Reiterates Overweight on DocGo, Maintains $5 Price Target

Wells Fargo analyst Colin Langan maintains Magna International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGA#NYSE">MGA</a>) with a Equal-Weight and raises the price target from $43 to $44.

Wells Fargo Maintains Equal-Weight on Magna International, Raises Price Target to $44

Truist Securities analyst Brandon King maintains Columbia Banking System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NASDAQ">COLB</a>) with a Hold and lowers the price target from $29 to $28.

COLB

Truist Securities Maintains Hold on Columbia Banking System, Lowers Price Target to $28

Wells Fargo analyst Colin Langan maintains Lear (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEA#NYSE">LEA</a>) with a Equal-Weight and lowers the price target from $131 to $114.

Wells Fargo Maintains Equal-Weight on Lear, Lowers Price Target to $114

CC Lagator, co-founder of Options AI, shared his insights on the Friday&#8217;s episode of <a href="https://www.benzinga.com/premarket-prep">Benzinga&#8217;s PreMarket Prep</a>, cautioning traders to prepare for increased volatility in the week <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40948624/traders-brace-for-friday-volatility-as-over-5-trillion-in-options-expire-could-trip">following September&#8217;s &#8220;triple witching.&#8221; </a>
Hosted by Aaron Bry and Dennis Dick, the discussion highlighted how the massive expiration of key options contracts can drive unusual market activity and set the stage for turbulence ahead.
Triple witching, which occurs quarterly on the third Friday of March, June, September, and December, is when stock index futures, stock index options, and individual stock options expire simultaneously. 
This event often creates market turbulence, as traders scramble to close, roll over, or offset expiring contracts. 
Over $5 trillion in notional options, including $605 billion in single-stock options, are expected to expire during Friday's session.
Historically, triple witching has led to increased volatility and unusual price movements. The S&amp;P 500, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), closed in the red on the last three triple witching days:
<ul>
<li>June 21, 2024: S&amp;P 500 fell by 0.5%.</li>
<li>March 15, 2024: S&amp;P 500 dropped by 1%.</li>
<li>Dec. 15, 2023: S&amp;P 500 declined by 0.6%.</li>
</ul>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Witching Day &#x7C; PreMarket Prep" width="500" height="281" src="https://www.youtube.com/embed/Zq0gm-YmwUM?start=2238&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
<h2 class="wp-block-heading">Historical Weakness Post-Witching Week</h2>
During his appearance on <a href="https://www.benzinga.com/premarket-prep">Benzinga PreMarket Prep</a>, CC Lagator explained how the convergence of expiring options impacts the market.
&#8220;You might see some imbalances that you wouldn&#8217;t have seen on a normal day at the open,&#8221; CC Lagator said, highlighting how trading activity starts to unwind a couple of days before but accelerates toward the close of the session.
This often stems from big hedge funds and mutual funds rolling options positions into the next month, which can lead to increased volatility. He further noted that the market environment shifts drastically after triple witching, with traders facing a completely new landscape in the following week.
&#8220;Next week historically is a terrible week going back decades,&#8221; Lagator said, noting that the week after triple witching in September has rarely shown positive returns over the last 30 years.
With volatility expected to pick up, he cautioned that traders should brace for a challenging week due to the impact of unwinding positions on the broader market.
The conversation also turned to the Volatility Index (VIX), often referred to as the &#8220;fear gauge,&#8221; which CC Lagator described as being relatively low and attractive for call option buyers at these levels. 
&#8220;The VIX is at 16 right now, it&#8217;s not high,&#8221; CC Lagator stated, adding that it trades below its long-term average of 19. 
&#8220;If this was July and we were at all-time highs, the VIX would probably be 13,&#8221; he noted, attributing the slight uptick to recent market events and the seasonal volatility that accompanies the fall months. 
&#8220;For traders looking at the next month and a half, there&#8217;s not much worry about volatility dropping much lower than where it is now,&#8221; Lagator predicted, adding that &#8220;we're probably not seeing it hit 12 until Christmas.&#8221;
Lagator advised that traders could use this period of low volatility to their advantage when considering options positions. 
&#8220;If you were buying at-the-money options right now, you probably don&#8217;t have much to worry about in terms of volatility going much lower,&#8221; he said, emphasizing the stability of current volatility levels as a potential buying opportunity for those seeking to hedge or position themselves for a breakout.
A similar view has also been shared by Goldman Sachs, which estimates that, given macroeconomic conditions, the VIX should be at 24.5 points.
The investment bank issued a recommendation for investors to hedge their portfolios using VIX calls. Specifically, Goldman Sachs analysts advise buying CBOE Volatility Index (VIX) November calls at a strike price of 18.
<h2 class="wp-block-heading">S&amp;P 500&#8217;s 5 Top Gainers, 5 Worst Laggards After Friday&#8217;s Market Open</h2>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Chg %</td>
</tr>
<tr>
<td>Constellation Energy Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>)</td>
<td>13.34%</td>
</tr>
<tr>
<td>Vistra Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>)</td>
<td>7.67%</td>
</tr>
<tr>
<td>NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>)</td>
<td>6.07%</td>
</tr>
<tr>
<td>CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>)</td>
<td>4.47%</td>
</tr>
<tr>
<td>Exelon Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXC#NASDAQ">EXC</a>)</td>
<td>2.35%</td>
</tr>
</tbody>
</table>
</figure>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Chg %</td>
</tr>
<tr>
<td>FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>)</td>
<td>-14.68%</td>
</tr>
<tr>
<td>Old Dominion Freight Line, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NYSE">ODFL</a>)</td>
<td>-4.72%</td>
</tr>
<tr>
<td>Viatris Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NYSE">VTRS</a>)</td>
<td>-4.66%</td>
</tr>
<tr>
<td>Lennar Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>)</td>
<td>-4.61%</td>
</tr>
<tr>
<td>ON Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>)</td>
<td>-4.43%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Data as of 10:00 a.m. ET</figcaption></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/asia/24/09/40957270/interest-rate-divergence-weakens-dollar-to-17-month-low-against-yuan-xpeng-li-auto-among-4-stock-mov">Interest Rate Divergence Weakens Dollar To 17-Month Low Against Yuan: XPeng, Li Auto Among 4 Stock Movers</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Broad U.S. Equity ETFs

Options

ETFs

CRWD

ODFL

VTRS

EXCLUSIVE: Options Expert Warns Of 'Terrible Week' After Friday's Triple Witching

Truist Securities analyst Brandon King maintains Cathay General (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATY#NASDAQ">CATY</a>) with a Hold and raises the price target from $45 to $47.

CATY

Truist Securities Maintains Hold on Cathay General, Raises Price Target to $47

Wells Fargo analyst Colin Langan maintains Autoliv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALV#NYSE">ALV</a>) with a Equal-Weight and lowers the price target from $103 to $102.

Wells Fargo Maintains Equal-Weight on Autoliv, Lowers Price Target to $102

Chewy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) shares are trading lower by 4.38% to $29.74 during Friday&#8217;s session after the company announced the public offering of shares by a selling stockholder and a <a href="https://www.benzinga.com/news/24/09/40949015/chewy-stock-is-sliding-after-hours-whats-going-on">concurrent share repurchase</a>.
What To Know: Chewy late Thursday announced the pricing of an underwritten offering of 16,666,667 shares of its Class A common stock at $30.00 per share by its largest shareholder, Buddy Chester Sub LLC, affiliated with BC Partners. 
The underwriter has a 30-day option to buy an additional 2.5 million shares. Chewy will not sell any shares or receive any proceeds from this offering.
Read Also: <a href="https://www.benzinga.com/markets/asia/24/09/40957270/interest-rate-divergence-weakens-dollar-to-17-month-low-against-yuan-xpeng-li-auto-among-4-stock-mov">Interest Rate Divergence Weakens Dollar To 17-Month Low Against Yuan</a>
What Else: Additionally, Chewy will repurchase $300 million of its Class A stock from the same seller at the offering price in a separate transaction. 
This repurchase, approved by Chewy&#8217;s independent board members, is separate from the company&#8217;s existing $500 million repurchase program. Upon completion, the repurchased shares will be cancelled. The offering is expected to close by September 23.
Before the offering, Chewy had about 143 million Class A shares and 275 million Class B shares outstanding. Post-transaction, it will have approximately 160 million Class A shares and 248 million Class B shares.
Read Also: <a href="https://www.benzinga.com/news/24/09/40958207/how-apple-stock-could-gain-from-fridays-s-p-500-rebalancing-what-investors-should-know">How Apple Stock Could Gain From Friday&#8217;s S&amp;P 500 Rebalancing: What Investors Should Know</a>
<h2 class="wp-block-heading">How To Buy CHWY Stock</h2>
By now you're likely curious about how to participate in the market for Chewy &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. 
In the the case of Chewy, which is trading at $29.9 as of publishing time, $100 would buy you 3.34 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, CHWY has a 52-week high of $39.10 and a 52-week low of $14.68.

CHWY

Why Chewy (CHWY) Stock Is Trading Lower

RBC Capital analyst Brian Abrahams reiterates Corbus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) with a Outperform and maintains $82 price target.

CRBP

RBC Capital Reiterates Outperform on Corbus Pharmaceuticals, Maintains $82 Price Target

Wells Fargo analyst Colin Langan maintains Adient (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADNT#NYSE">ADNT</a>) with a Overweight and lowers the price target from $29 to $27.

ADNT

Wells Fargo Maintains Overweight on Adient, Lowers Price Target to $27

Truist Securities analyst Michael Swartz maintains Camping World Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWH#NYSE">CWH</a>) with a Buy and raises the price target from $26 to $28.

Truist Securities Maintains Buy on Camping World Holdings, Raises Price Target to $28

Wells Fargo analyst Jason Haas maintains FactSet Research Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) with a Equal-Weight and raises the price target from $435 to $503.

Wells Fargo Maintains Equal-Weight on FactSet Research Systems, Raises Price Target to $503

On Saturday, Pfizer Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>) presented positive trial data for experimental drug designed for patients suffering from&nbsp;cancer cachexia during the European Society for Medical Oncology 2024 Congress. Affecting as many as&nbsp;9 million people across the globe, cancer cachexia is a life-threatening condition that causes cancer patients to lose appetite and consequently, weight.
<h3>Paving The Way For The World&rsquo;s First Treatment For Cancer Cachexia</h3>
The mid-stage trial results showed that patients that were treated with the experimental drug that Pfizer developed showed improvements in body weight, muscle mass, quality of life and physical function. Therefore, the drug which is a monoclonal antibody called ponsegromab could become the first treatment approved in the U.S. specifically&nbsp;for this condition. This would translate to Pfizer saving many lives as 80% of cancer patients who suffer from this condition are not expected to make it beyond a year of being diagnosed as they are unable to meet their body&rsquo;s energy and nutritional needs. The condition also makes the general treatment of cancer less effective and lowers the odds of survival as it leaves the patient even weaker, unable to tolerate the treatment.&nbsp;
<h3>The Trial</h3>
Involving&nbsp;187 patients diagnosed with non-small cell lung cancer, pancreatic cancer or colorectal cancer and high levels of a key driver of cachexia, patients who took the highest dose of ponsegromab, which is 400 milligrams, over the course of 12 weeks&nbsp;observed a&nbsp;5.6% increase in weight compared to those patients who received a placebo. Patients who took lower doses of 200 or 100-milligrams observed roughly 3.5% and 2% increase in body weight compared to the placebo group. Pfizer added that experts consider weight gain greater than 5% as a &ldquo;clinically meaningful difference&rdquo; when it comes to cancer patients with cachexia and noted that increased appetite and improvement in physical activity is what was most encouraging.&nbsp;&nbsp;The good news is that no significant side effects of the drug were observed. Pfizer is planning to begin late-stage development studies in 2025 that can be used to file for approval, while also studying the effect of ponsegromab in a phase two trial in patients diagnosed with heart failure.
Catching up to Moderna Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrna#NASDAQ">MRNA</a>) and others on the cancer front.
It&rsquo;s no secret that Pfizer has turned to oncology in an effort to combat the Covid-19 decline.&nbsp;&nbsp;To turn its business around, it targeted as many as 8 blockbuster cancer drugs by the end of this decade. One of its main Covid-19 rivals, Moderna is expected to launch its experimental cancer vaccine as early as next year.
Together with Merck &amp; Co Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mrk#NYSE">MRK</a>), Moderna is currently testing their combined treatment for advanced melanoma in a large-scale Phase III trial. Approximately, 1,089 patients at more than 165 sites across the globe will be tested to assess the efficiency of the experimental vaccine mRNA-4157 that Moderna and Merck co-developed, along with the immunotherapy drug, Keytruda, that is already a blockbuster for Merck. The study will assess the efficiency of the treatment that Moderna and Merck created in achieving a recurrence-free survival, while the secondary endpoints are distant metastasis-free survival, along with overall survival and safety.
&nbsp;
Codenamed mRNA-4359, Moderna also designed a vaccine to boost people&#39;s immunity to better recognize and fight a variety of advanced solid tumor cancers. During the above-mentioned congress that took place in Barcelona, Spain, on Saturday, researchers at King&rsquo;s College London&nbsp;presented&nbsp;Phase I/II trial to test Moderna&rsquo;s vaccine candidate, more precisely its ability to sensitize the immune system to two specific proteins commonly common in tumor cells as well as other cells that suppress the immune system, PD-L1 and IDO1.&nbsp;From 16 patients diagnosed with advanced lung cancer, melanoma, and other solid tumors who were able to have their responses measured, eight patients showed no signs of their tumors growing and there were no new tumors formed. In addition, tests found that the vaccine seemed to generate a noticeable increase in immune cells that could recognize PD-L1 and IDO1.&nbsp;While more data will be needed to know whether mRNA-4359 can work as hoped, these results are promising.&nbsp;
The future of cancer treatment looks bright.
Besides vaccines designed to help patients combat cancer, Mainz Biomed N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mynz#NASDAQ">MYNZ</a>) advanced on the early screening and prevention front. A molecular genetics diagnostic company specialized in the early detection of cancer,&nbsp;Mainz Biomed is currently seeking FDA approval for its colorectal cancer test, ColoAlert. With an innovative portfolio of mRNA biomarkers, Mainz Biomed is promising to set a new gold standard for noninvasive detection of advanced adenoma, which is a well-known pre-cancerous condition. This week, Mainz Biomed announced its newest Brand Ambassador,&nbsp;Petra Smeltzer Starke, known serving as&nbsp;General Counsel to the White House Council of Economic Advisors and Senior Advisor to President Obama. Ms. Smeltzer Starke&rsquo;s role will be to help to raise awareness on the importance of early detection of colorectal cancer. If diagnosed early, up to 90% of colorectal cancer cases can be treated successfully. Therefore, early screening makes all the difference.&nbsp;
By the looks of it, years ahead seem promising when it comes to revolutionizing cancer treatment.&nbsp;
DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.
This article is from an unpaid external contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.

Biotech

Penny Stocks

Eurozone

Markets

General

MRNA

MYNZ

Pfizer Advances On Its Cancer Journey

Truist Securities analyst Brandon King maintains Cadence Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CADE#NYSE">CADE</a>) with a Buy and lowers the price target from $38 to $37.

CADE

Truist Securities Maintains Buy on Cadence Bank, Lowers Price Target to $37

Cantor Fitzgerald analyst Sarah James reiterates Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Overweight and maintains $90 price target.

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

RCMW Group Inc Ordinary Shares

News

Latest news for RCMW Group Inc Ordinary Shares (OTC:RCMW) Stock